Related Experiment Video
Updated: Jul 26, 2026
11:28
Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
Published on: March 13, 2015
41.7K
STUDIES ON HBsAG IN HIV SEROPOSITIVE CASES
1Senior Adviser; (Derm and Ven), Command Hospital, Southern Command, Pune 411 040.
Medical Journal, Armed Forces India
|August 4, 2017
Summary
Hepatitis B virus surface antigen (HBsAg) was found in 10.2% of patients with human immunodeficiency virus (HIV). Nearly half of these patients developed a chronic carrier state, highlighting a significant co-infection burden.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Human immunodeficiency virus (HIV) infection is a global health concern.
- Hepatitis B virus (HBV) co-infection is common in HIV-positive individuals.
- Understanding the prevalence and outcomes of HBV in HIV patients is crucial for clinical management.
Purpose of the Study:
- To determine the prevalence of hepatitis B virus surface antigen (HBsAg) in HIV-infected patients.
- To assess the development of a chronic carrier state in HIV patients with HBsAg positivity.
- To provide data on the clinical significance of HBV/HIV co-infection.
Main Methods:
- Screening of 255 patients with HIV for HBsAg.
- Follow-up of HBsAg-positive patients every 6 months.
- Monitoring for the development of a carrier state.
Main Results:
- 10.2% of HIV-seropositive patients screened were positive for HBsAg.
- Among HBsAg-positive HIV patients, 47.6% developed a carrier state.
- This indicates a substantial rate of HBV persistence in this population.
Conclusions:
- A significant proportion of HIV patients harbor occult or active HBV infection.
- The high rate of carrier state development underscores the need for vigilant monitoring and management of HBV in HIV co-infected individuals.
- Early detection and intervention strategies are essential to mitigate long-term complications of HBV/HIV co-infection.
